Abstract Background Circulating tumor cells (CTCs) are a promising source of biological
information in cancer. Data correlating PD-L1 expression in CTCs with patients' response to …

Aim The treatment of non-small-cell lung cancer has changed after the development of the
immune checkpoint inhibitors. Although the most studied biomarker is PD-L1 expression, its …

Introduction This study investigated whether programmed death‐ligand 1 (PD‐L1)
expression of circulating tumor cells (CTCs) in peripheral blood can serve as a predictive …

Over the last decade, the immune checkpoint blockade targeting the programmed death
protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis has improved progression-free …

Abstract Introduction Immune checkpoint inhibitors (ICIs) have significantly improved the
prognosis of non-small cell lung cancer (NSCLC). However, only a limited proportion of …

Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1)
have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 …

Background Immune checkpoint inhibitors (ICIs) have become a high-profile regimen for
malignancy recently. However, only a small subpopulation obtains long-term clinical benefit …

PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1
blockade anticancer therapies, particularly for lung cancer. However, the reliability of this …

Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy,
and radiotherapy have been the standard treatment for lung cancer, and targeted molecular …

Background Inhibitors of the PD-1/PD-L1 immune checkpoint have become a standard of
care in non-small cell lung cancer (NSCLC). Patient selection, currently based on PD-L1 …